初诊 ERBB2（HER2/neu）阳性乳腺癌患者的血清肿瘤坏死因子-α和白细胞介素-2浓度。

Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients.

机构信息

Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

出版信息

Int J Biol Markers. 2009 Jul-Sep;24(3):142-6. doi: 10.1177/172460080902400303.

DOI:10.1177/172460080902400303

PMID:19787624

Abstract

AIM

Cytokines have been associated with symptoms and adverse outcomes in breast cancer. Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, large tumor size, high grade, steroid receptor negativity, aneuploidy, high proliferation rate, and low overall survival in breast cancer. The aim of the study was to examine whether ERBB2 amplification has any effect on circulating levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) in breast cancer patients.

MATERIAL AND METHODS

Fifty patients with primary breast carcinoma, classified as either ERBB2 (+) or (-) by the fluorescence in situ hybridization (FISH) technique, were included in the study. Cytokines were studied by ELISA according to the procedure described in the commercial kit.

RESULTS

IL-2 levels were found significantly higher in ERBB2+ patients than in controls (p<0.05). A significant negative correlation existed between ERBB2 positivity and estrogen receptor status (p=0.004). Plasma TNF-alpha and IL-2 levels were positively correlated in ERBB2+ breast cancer patients (p<0.01).

CONCLUSION

The increase in IL-2 concentrations observed in our study suggests an activation of T cells by ERBB2 peptides.

摘要

目的

细胞因子与乳腺癌的症状和不良预后有关。表皮生长因子受体家族成员 ERBB2（c-erb-b2；以前称为 HER2/neu）的过度表达与淋巴结受累、肿瘤体积大、高分级、甾体受体阴性、非整倍体、高增殖率和整体生存率低有关。本研究旨在探讨 ERBB2 扩增是否对乳腺癌患者循环肿瘤坏死因子-α（TNF-α）和白细胞介素-2（IL-2）水平有任何影响。